Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #106827 on Amarantus Bioscience Holdings Inc (AMBS)
Sccrbrg
08/02/14 6:01 PM
#106829 RE: Solantey #106827
In its announcement, the agency tried to address such concerns, saying it would phase in the requirements over nine years and would focus oversight on the tests where a wrong result would pose the highest level of risk to patients. It would exempt tests for which there is no approved alternative and tests for rare diseases, which might be expensive to develop if required to go through F.D.A. review.
JPetroInc
08/02/14 7:30 PM
#106831 RE: Solantey #106827